Humacyte (NASDAQ:HUMA) CFO Sells $41,298.30 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CFO Dale Sander sold 45,887 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the chief financial officer owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. This represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Price Performance

HUMA opened at $1.05 on Friday. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte, Inc. has a 52-week low of $0.55 and a 52-week high of $2.93. The company has a 50 day moving average of $0.83 and a two-hundred day moving average of $1.04. The company has a market cap of $233.12 million, a P/E ratio of -1.84 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, analysts expect that Humacyte, Inc. will post -0.32 earnings per share for the current year.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Concurrent Investment Advisors LLC lifted its holdings in shares of Humacyte by 16.6% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock valued at $104,000 after acquiring an additional 8,500 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Humacyte by 50.3% in the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after buying an additional 11,411 shares in the last quarter. Independent Advisor Alliance lifted its holdings in Humacyte by 49.4% in the 3rd quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after buying an additional 11,991 shares in the last quarter. Prudential Financial Inc. acquired a new position in Humacyte in the 2nd quarter worth $28,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Humacyte by 21.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock worth $73,000 after buying an additional 13,175 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. BTIG Research reduced their target price on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen upgraded shares of Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.